Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daratumumab + dexamethasone
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
Daratumumab + dexamethasone is a combination regimen used primarily in the treatment of multiple myeloma, a type of blood cancer. Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of myeloma cells. By binding to CD38, daratumumab induces cell death through several immune-mediated mechanisms including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis. Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant properties; it helps reduce inflammation and manage side effects associated with cancer therapies. This combination is often used in patients who have received at least one prior therapy for multiple myeloma or are not eligible for stem cell transplant[1][4][5][8].
- Other names
- Etoile du Nord
02
Targets
CD38 (Cluster of Differentiation 38)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on daratumumab + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daratumumab + dexamethasone.